CAMP4 Therapeutics【CAMP】銘柄情報

CAMP4 Therapeutics Corporation (CAMP) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

4.4307

( 2.09% )

買値

4.43

売値

4.47

出来高

114,982

4.18 日の範囲 4.50

1.32 52 週間の範囲 7.75

時価総額

230.068M

前日終値

4.34

始値

4.38

時刻

100

4.4307

(formt)

最終取引時間

財務取引量

US$ 500,825

VWAP

4.3557

平均取引量 (3 か月)

US$ 155,680

発行済株式数

51,925,800

配当利回り

PER

-2.02

1 株当たり利益 (EPS)

-2.17

歳入

3.93M

純利益

-86.3M

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also de... Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. 詳細を表示

セクター

業界

ウェブサイト

www.camp4tx.com

本社

Cambridge, United States

設立

2026

CAMP4 Therapeutics Corporation is listed in the sector of the ナスダック市場 with ticker CAMP. The last closing price for CAMP4 Therapeutics was US$4.34. Over the last year, CAMP4 Therapeutics shares have traded in a share price range of US$ 1.32 to US$ 7.75.

CAMP4 Therapeutics currently has 51,925,800 shares in issue. The market capitalisation of CAMP4 Therapeutics is US$230.07 million. CAMP4 Therapeutics has a price to earnings ratio (PE ratio) of -2.02.

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving...

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”...

Form 8-K - Current report

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”...

Form 8-K - Current report

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.3307	8.06585365854	4.1	4.5792	3.74	832878	4.20673466	CS
4	0.2407	5.7446300716	4.19	5.25	3.74	340231	4.18630639	CS
12	-0.0693	-1.54	4.5	5.25	3.74	162657	4.24260512	CS
26	-1.7893	-28.7668810289	6.22	7.75	3.3	173137	5.01748158	CS
52	3.0707	225.786764706	1.36	7.75	1.32	314349	3.56849331	CS
156	3.3907	326.028846154	1.04	12.3	0.1349	280762	2.19680096	CS
260	-8.4493	-65.6001552795	12.88	12.88	0.1349	295700	3.57835994	CS